Effects of the insulin sensitizer pioglitazone on menstrual irregularity, insulin resistance and hyperandrogenism in young women with polycystic ovary syndrome

Journal of Pediatric and Adolescent Gynecology

Volumn 27, Issue 3, 2014, Pages 177-182

  Stabile, Gaspare ^a   Borrielli, Irene ^b   Artenisio, Alfredo Carducci ^a   Bruno, Lucia Maria ^a   Benvenga, Salvatore ^a   Giunta, Loretta ^a   La Marca, Antonio ^c   Volpe, Annibale ^c   Pizzo, Alfonsa ^b  

^a UNIVERSITY OF MESSINA   (Italy)

^b UNIVERSITY OF MESSINA   (Italy)

^c UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

Adiponectin; Insulin resistence; Pioglitazone; Polycystic ovary syndrome

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; ANDROSTENEDIONE; C REACTIVE PROTEIN; ESTRADIOL; FIBRINOGEN; FOLLITROPIN; GLYCOSYLATED HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LUTEINIZING HORMONE; PIOGLITAZONE; PRASTERONE; PROGESTERONE; TESTOSTERONE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT;

ACNE; ADULT; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GLUCOSE TOLERANCE TEST; HIRSUTISM; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; MENSTRUAL CYCLE; MENSTRUAL IRREGULARITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; ORAL GLUCOSE TOLERANCE TEST; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL; YOUNG ADULT; ADOLESCENT; BLOOD; DRUG EFFECTS; HYPERANDROGENISM; MENSTRUATION DISTURBANCES; METABOLISM; POLYCYSTIC OVARY SYNDROME; RANDOMIZED CONTROLLED TRIAL;

ADIPONECTIN; ADOLESCENT; C-REACTIVE PROTEIN; FEMALE; FIBRINOGEN; HIRSUTISM; HUMANS; HYPERANDROGENISM; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; LUTEINIZING HORMONE; MENSTRUAL CYCLE; MENSTRUATION DISTURBANCES; POLYCYSTIC OVARY SYNDROME; THIAZOLIDINEDIONES; YOUNG ADULT;

EID: 84899885870     PISSN: 10833188     EISSN: 18734332     Source Type: Journal    
DOI: 10.1016/j.jpag.2013.09.015     Document Type: Article

References (34)

1. Azziz R., Woods K.S., Reyna R., et al. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab 2004, 89:2745.
2. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004, 81:19. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group.
3. Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev 1997, 18:774.
4. Dunaif A., Segal K.R., Futterweit W., et al. Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes 1998, 38:1165.
5. Willis D., Mason H., Gilling-Smith C., et al. Modulation by insulin of follicle-stimulating hormone and luteinizing hormone actions in human granulosa cells of normal and polycystic ovaries. J Clin Endocrinol Metab 1996, 81:302.
6. Apridonidze T., Essah P.A., Iuorno M.J., et al. Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2005, 90:1929.
7. Coviello A.D., Legro R.S., Dunaif A. Adolescent girls with polycystic ovary syndrome have an increased risk of the metabolic syndrome associated with increasing androgen levels independent of obesity and insulin resistance. Clin Endocrinol Metab 2006, 91:492.
8. Danesh J., Wheeler J.G., Hirschfield G.M., et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 2004, 350:1387.
9. Talbott E.O., Zborowski J.V., Rager J.R., et al. Evidence for an association between metabolic cardiovascular syndrome and coronary and aortic calcification among women with polycystic ovary syndrome. Clin Endocrinol Metab 2004, 89:5454.
10. Allen H.F., Mazzoni C., Heptulla R.A., et al. Randomized controlled trial evaluating response to metformin versus standard therapy in the treatment of adolescents with polycystic ovary syndrome. J Pediatr Endocrinol Metab 2005, 18:761.
11. Genazzani A.D., Lanzoni C., Ricchieri F., et al. Metformin administration is more effective when non-obese patients with polycystic ovary syndrome show both hyperandrogenism and hyperinsulinemia. Gynecol Endocrinol 2007, 23:146.
12. Stumvoll M., Haring H.U. Glitazones: clinical effects and molecular mechanisms. Ann Med 2002, 34:217.
13. Brettenthaler N., De Geyter C., Huber P.R., et al. Effect of the insulin sensitizer pioglitazone on insulin resistance, hyperandrogenism, and ovulatory dysfunction in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2004, 89:3835.
14. Garmes H.M., Tambascia M.A., Zantut-Wittmann D.E. Endocrine-metabolic effects of the treatment with pioglitazone in obese patients with polycystic ovary syndrome. Gynecol Endocrinol 2005, 21:317.
15. Koo Y.A., Shin S.Y., Yoon B.K., et al. Pioglitazone for treating polycystic ovary syndrome in non-obese women of reproductive age with different clinical presentations. Gynecol Endocrinol 2007, 23:461.
16. Aroda V.R., Ciaraldi T.P., Burke P., et al. Metabolic and hormonal changes induced by pioglitazone in polycystic ovary syndrome: a randomized, placebo-controlled clinical trial. Clin Endocrinol Metab 2009, 94:469.
17. Matsuda M., Shimomura I., Sata M., et al. Role of adiponectin in preventing vascular stenosis. The missing link of adipo-vascular axis. J Biol Chem 2002, 277(40):37487.
18. Fasshauer M., Paschke R. Regulation of adipocytokines and insulin resistance. Diabetologia 2003, 46:1594.
19. Spranger J., Mohlig M., Wegewitz U., et al. Adiponectin is independently associated with insulin sensitivity in women with polycystic ovary syndrome. Clin Endocrinol (Oxf) 2004, 61:738.
20. Imatoh T., Miyazaki M., Momose Y., et al. Adiponectin levels associated with the development of hypertension: a prospective study. Hypertens Res 2008, 31:229.
21. Carmina E., Orio F., Palomba S., et al. Evidence for altered adipocyte function in polycystic ovary syndrome. Eur J Endocrinol 2005, 152:389.
22. Glintborg D., Frystyk J., Højlund K., et al. Total and high molecular weight (HMW) adiponectin levels and measures of glucose and lipid metabolism following pioglitazone treatment in a randomized placebo-controlled study in polycystic ovary syndrome. Clin Endocrinol (Oxf) 2008, 68:165.
23. Matthews D.R., Hosker J.P., Rudenski A.S., et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentration in man. Diabetes 1985, 28:412.
24. Matsuda M., De Fronzo R. Insulin sensitivity indices obtained from oral glucose tolerance testing. Diabetes Care 1999, 22:1462.
25. De Fronzo R.A., Tobin J.D., Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 1979, 23:E214.
26. Gambineri A., Semple R.K., Forlani G., et al. Monogenic polycystic ovary syndrome due to a mutation in the lamin A/C gene is sensitive to thiazolidinediones but not to metformin. Eur J Endocrinol 2008, 159:347.
27. Naka K.K., Kalantaridou S.N., Kravariti M., et al. of the insulin sensitiziers metformin and pioglitazone on endothelial function in young women with polycystic ovary syndrome: a prospective randomized study. Fertil Steril 2011, 95:203.
28. Ortega-González C., Luna S., Hernández L., et al. Responses of serum androgen and insulin resistance to metformin and pioglitazone in obese, insulin-resistant women with polycystic ovary syndrome. J Clin Endocrinol Metab 2005, 90:1360.
29. Pai J.K., Pischon T., Ma J., et al. Inflammatory markers and the risk of coronary heart disease in men and women. N Engl J Med 2004, 351:2599.
30. Lemieux I., Pascot A., Prud'homme D., et al. Elevated C-reactive protein: another component of the atherothrombotic profile of abdominal obesity. Arterioscler Thromb Vasc Biol 2001, 21:961.
31. Naka K.K., Kalantaridou S.N., Kravariti M., et al. Effect of the insulin sensitizers metformin and pioglitazone on endothelial function in young women with polycystic ovary syndrome: a prospective randomized study. Fertil Steril 2011, 95:203.
32. Rizzo M., Berneis K., Carmina E., et al. How should we manage atherogenic dyslipidemia in women with polycystic ovary syndrome?. Am J Obstet Gynecol 2008, 198:28.e1.
33. Kelly C.C., Lyall H., Petrie J.R., et al. Low grade chronic inflammation in womenwith polycystic ovarian syndrome. J Clin Endocrinol Metab 2001, 86:2453.
34. Du Q., Wang Y.J., Yang S., et al. A systematic review and meta-analysis ofrandomized controlled trials comparing pioglitazone versus metformin inthetreatment of polycystic ovary syndrome. Curr Med Res Opin 2012, 28:723.